Jubilant Ingrevia Ltd Valuation Shifts to Attractive Amid Market Volatility

Valuation Metrics Reflect Renewed Appeal

As of 16 Feb 2026, Jubilant Ingrevia’s price-to-earnings (P/E) ratio stands at 36.92, a figure that, while elevated in absolute terms, is considered attractive when benchmarked against its specialty chemicals peers. This contrasts with companies such as J B Chemicals & Pharmaceuticals, which trades at a P/E of 40.38 and is rated very expensive, and Gland Pharma at 33.91, also deemed very expensive. The company’s price-to-book value (P/BV) ratio of 3.34 further supports this valuation upgrade, signalling a more reasonable premium over book value compared to sector heavyweights.

Other valuation multiples reinforce this narrative. The enterprise value to EBITDA (EV/EBITDA) ratio of 19.80 is competitive within the sector, especially when compared to Ajanta Pharma’s 26.28 and Pfizer’s 22.74. Meanwhile, the PEG ratio of 1.11 indicates a balanced valuation relative to earnings growth expectations, markedly lower than peers like AstraZeneca Pharma, which carries a PEG of 6.51, suggesting overvaluation concerns.

Financial Performance and Returns Contextualise Valuation

Jubilant Ingrevia’s return on capital employed (ROCE) and return on equity (ROE) stand at 10.56% and 9.47%, respectively. These figures, while modest, reflect steady operational efficiency and shareholder returns in a challenging market environment. Dividend yield remains low at 0.78%, consistent with the company’s growth-oriented profile.

From a price perspective, the stock closed at ₹637.20 on 16 Feb 2026, down 4.23% from the previous close of ₹665.35. The 52-week trading range spans ₹556.55 to ₹851.85, indicating significant volatility but also room for upside from current levels. Intraday trading on the day saw a high of ₹665.20 and a low of ₹637.20, underscoring the recent selling pressure.

Comparative Returns Highlight Relative Underperformance

Examining returns over various periods reveals a mixed picture. Jubilant Ingrevia outperformed the Sensex over the past week with a 3.72% gain versus the benchmark’s 1.14% loss. However, over one month and year-to-date periods, the stock underperformed, declining 6.89% and 9.49%, respectively, compared to Sensex losses of 1.20% and 3.04%. Over a one-year horizon, the stock’s return of -2.97% contrasts with the Sensex’s robust 8.52% gain. Longer-term returns over three years are broadly in line with the benchmark, with Jubilant Ingrevia posting a 36.31% gain against Sensex’s 36.73%.

Mojo Score and Rating Dynamics

MarketsMOJO assigns Jubilant Ingrevia a Mojo Score of 28.0, reflecting a strong sell recommendation. This represents a downgrade from the previous sell rating on 5 Feb 2026, signalling increased caution among analysts. The market capitalisation grade remains low at 3, indicating limited scale relative to larger industry players. This rating juxtaposes the attractive valuation grade, suggesting that while the stock may be undervalued on multiples, other factors such as earnings quality, growth prospects, or sector risks weigh heavily on sentiment.

Sector and Peer Comparison: Valuation Versus Quality

Within the specialty chemicals sector, Jubilant Ingrevia’s valuation stands out as comparatively attractive, especially against peers rated expensive or very expensive. For instance, Wockhardt trades at a staggering P/E of 176.5, while Piramal Pharma is classified as fair but is currently loss-making, complicating direct valuation comparisons. The company’s EV to capital employed ratio of 2.87 and EV to sales of 2.56 further underscore its relative efficiency in capital utilisation and revenue generation.

However, the strong sell Mojo Grade indicates concerns beyond valuation, possibly linked to earnings volatility, competitive pressures, or macroeconomic headwinds affecting the specialty chemicals industry. Investors should weigh these factors carefully against the apparent valuation opportunity.

Outlook and Investment Considerations

Jubilant Ingrevia’s shift to an attractive valuation grade suggests a potential entry point for value-oriented investors seeking exposure to the specialty chemicals sector. The company’s moderate ROCE and ROE, combined with reasonable multiples, provide a foundation for cautious optimism. Yet, the negative short-term returns and strong sell rating highlight ongoing risks that could temper near-term performance.

Investors should monitor upcoming quarterly results and sector developments closely, as any improvement in earnings quality or growth visibility could catalyse a re-rating. Conversely, persistent margin pressures or regulatory challenges may prolong the subdued sentiment.

Conclusion: Valuation Opportunity Amid Caution

Jubilant Ingrevia Ltd’s recent valuation upgrade to attractive, driven by improved P/E and P/BV ratios relative to peers and historical levels, presents a compelling case for investors seeking value in the specialty chemicals sector. Despite this, the company’s strong sell Mojo Grade and recent share price weakness underscore the need for prudence. The stock’s mixed return profile and modest profitability metrics suggest that while the price may be appealing, underlying business challenges remain.

For investors with a higher risk tolerance and a long-term horizon, Jubilant Ingrevia could represent a strategic addition, particularly if operational improvements materialise. However, those prioritising stability and growth may prefer to consider alternative stocks within the sector or broader market, as indicated by comparative analyses.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →